Radiation plus glofitamab for relapsed large B-cell lymphoma with large tumors
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of large B-cell lymphoma that is CD20-positive (a protein on the cancer cells) and has come back after or not responded to at least one prior treatment that included rituximab.
- You have a bulky tumor (larger than about 2.4 inches across) or a high total amount of active lymphoma on a PET scan.
- You are in fairly good health (able to do daily activities with little or no help).
- You have not had radiation to the chest or heart area before.
- You do not have active lymphoma in the brain or spinal fluid.
- You are not pregnant or breastfeeding and agree to use effective birth control during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
This trial tests a combination of three targeted drugs (tafasitamab, polatuzumab vedotin, and glofitamab) as a first treatment for diffuse large B-cell lymphoma or high-grade B-cell lymphoma. It aims to see if this approach can be effective without standard chemotherapy.
This trial tests a combination of two drugs (glofitamab, gemcitabine, oxaliplatin) followed by liso-cel (a CAR T-cell therapy) for people with large B-cell lymphoma who have only had one prior treatment and whose lymphoma came back. The goal is to see if this approach works better than standard treatments.
This trial tests combining radiation therapy with a drug called glofitamab (a type of immunotherapy) for patients whose diffuse large B-cell lymphoma (DLBCL) has returned or stopped responding to previous treatments. The goal is to see if adding radiation to this newer drug helps control the cancer better.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.